Then, the Tumor Immune Dysfunction and Exclusion algorithm predicted good responsiveness to immune checkpoint inhibitors in drug-resistant prostate cancers with the low-GAD1 genotype (p = 3.5e−05) (Fig. 5H). The gene discussed is GAD1; the disease is neoplasm.